In 226 patients with untreated unresectable hepatocellular carcinoma, adding ipilimumab to atezolizumab plus bevacizumab gave a 24-week objective response of 30% vs 27%, missing the phase 3 threshold; treatment-related deaths 5% vs 0%.
RCTn = 229
Merle et al. Addition of ipilimumab to atezolizumab plus bevacizumab in advanced hepatocellular carcinoma (PRODIGE 81-FFCD 2101-TRIPLET HCC): phase 2 results from a randomised, multicentre, open-label, phase 2-3 trial